Mark Coleman Sells 6,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Posted by Stanley Muller on Jun 3rd, 2026

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) Director Mark Coleman sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $230.30, for a total transaction of $1,381,800.00. Following the completion of the sale, the director directly owned 35,140 shares in the company, valued at $8,092,742. This represents a 14.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Mark Coleman also recently made the following trade(s):

On Tuesday, June 2nd, Mark Coleman sold 5,537 shares of Axsome Therapeutics stock. The stock was sold at an average price of $223.39, for a total transaction of $1,236,910.43.
On Friday, May 29th, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The stock was sold at an average price of $233.46, for a total transaction of $1,400,760.00.

Axsome Therapeutics Price Performance

Shares of AXSM stock traded down $8.09 during trading hours on Tuesday, hitting $222.16. 603,813 shares of the company’s stock were exchanged, compared to its average volume of 694,341. The company has a market capitalization of $11.43 billion, a PE ratio of -59.56 and a beta of 0.59. Axsome Therapeutics, Inc. has a 12-month low of $96.09 and a 12-month high of $238.56. The business’s 50 day simple moving average is $196.96 and its 200-day simple moving average is $176.15. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). The business had revenue of $191.20 million for the quarter, compared to analysts’ expectations of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.Axsome Therapeutics’s revenue was up 57.4% compared to the same quarter last year. On average, equities research analysts anticipate that Axsome Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AXSM. Kemnay Advisory Services Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $31,000. Hollencrest Capital Management grew its holdings in shares of Axsome Therapeutics by 400.0% in the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after purchasing an additional 160 shares during the last quarter. Optiver Holding B.V. grew its holdings in shares of Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after purchasing an additional 130 shares during the last quarter. Ameriflex Group Inc. bought a new position in shares of Axsome Therapeutics in the fourth quarter worth approximately $37,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of Axsome Therapeutics in the third quarter worth approximately $38,000. Institutional investors own 81.49% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wells Fargo & Company lifted their price target on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 5th. Royal Bank Of Canada lifted their price target on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday, May 4th. Deutsche Bank Aktiengesellschaft set a $280.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, May 5th. Finally, UBS Group lifted their price target on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $251.26.

Get Our Latest Report on AXSM

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.